Executive Summary
Cell MedX Corp (CMXC) reported QQ3 2024 results with an unusual top-line presentation. The income statement shows an operating income of $119,971 and net income of $119,971, alongside an EBITDA reading of $(57,775) and a depreciation figure presented as a negative $177,746. Revenue is not disclosed in the provided data, creating a conspicuous gap between topline and reported profitability. On a cash basis, operating cash flow was negative at $(37,945), while financing activities supplied a net $95,000, yielding a net cash increase of $57,054 for the period and ending cash of $79,677. The balance sheet reveals extreme leverage and a severely distressed liquidity position: total current liabilities of $791.9 million versus cash and equivalents of $79.7 thousand, a current ratio of 0.103 and a cash ratio of 0.101, and a stockholders’ deficit of $(709.9) million despite a cash runway supported by financing activity. The company shows negative retained earnings of $(10.17) million and a negative total stockholders’ equity, indicating fragile balance-sheet fortitude and a dependence on external financing to keep operations afloat. YoY and QoQ metric upgrades in operating income and net income (213.36% and 381.87% for operating income; 201.53% and 298.15% for net income) suggest some degree of improved profitability relative to prior periods, but the top-line gap, liquidity stress, and negative equity framework raise material investment risk. Management commentary is not provided in the data set; consequently, the narrative risk remains elevated until the company discloses revenue recognition, accounting treatment of depreciation, and any non-operating income contributing to the reported net income. Investors should monitor liquidity evolution, capital-structure remediation, and any monetization milestones for CMXC’s eBalance ecosystem in the diabetes and neurovascular therapy space.
Key Performance Indicators
QoQ: 381.87% | YoY:213.36%
QoQ: 298.15% | YoY:201.53%
QoQ: 390.00% | YoY:252.63%
Key Insights
Revenue and Gross Profit: Revenue is not disclosed in QQ3 2024 within the provided data; gross profit and gross margin are not reported in the same quarter. This creates a top-line ambiguity that hampers an apples-to-apples profitability assessment.
Operating Performance: Operating income reported at $119,971 for QQ3 2024, with a reported EBITDA of $(57,775) and a depreciation/debt treatment reflected as $(177,746) in the period. The discrepancy between positive operating income and negative EB...
Financial Highlights
Revenue and Gross Profit: Revenue is not disclosed in QQ3 2024 within the provided data; gross profit and gross margin are not reported in the same quarter. This creates a top-line ambiguity that hampers an apples-to-apples profitability assessment.
Operating Performance: Operating income reported at $119,971 for QQ3 2024, with a reported EBITDA of $(57,775) and a depreciation/debt treatment reflected as $(177,746) in the period. The discrepancy between positive operating income and negative EBITDA suggests potential non-cash charges or unusual items that warrant a closer look at the statement of cash flows and non-operating adjustments.
Net Income and EPS: Net income reported as $119,971 and earnings per share (EPS) of $0.0029 for the quarter, with YoY EPS growth of 252.63% and QoQ growth of 390.00% in the earnings metric table. The positive earnings print notwithstanding the cash burn raises questions about recurring profitability versus one-off accounting entries.
Liquidity and Balance Sheet: Cash and cash equivalents of $79,677 versus total current liabilities of $791,864 yield a current ratio of 0.103 and a quick ratio of 0.103, implying near-term liquidity stress. Short-term debt stands at $321,998; total debt is $321,998. Negative equity of $(709,946) and retained earnings of $(10,170,306) indicate a fragile capital structure and significant cumulative losses.
Cash Flow: Net cash from operating activities is $(37,945). Change in working capital contributed $20,490 inflow, accounts payable contributed $16,923 inflow, and other working capital items were $3,567 inflow, but the overall OCF remained negative. Net cash provided by financing activities totaled $95,000, supporting the period’s cash balance and end-of-period liquidity.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Operating Income |
119.97K |
213.36% |
381.87% |
| Net Income |
119.97K |
201.53% |
298.15% |
| EPS |
0.00 |
252.63% |
390.00% |
Key Financial Ratios
operatingCashFlowPerShare
$-0
Management Commentary
No earnings call transcript was provided in the data set. As such, there are no management quotes or verbatim insights available to extract in this section. If a transcript becomes available, we will distill themes around strategy, execution milestones, and market conditions and align them with the quantified results.
Forward Guidance
Management guidance for CMXC is not present in the supplied data. Given the quarter’s reported numbers and the balance-sheet fragility, any forward-looking assessment hinges on: (1) revenue recognition clarity and top-line growth visibility for eBalance Pro/Home System platforms (professional and consumer segments); (2) ongoing cash-burn reduction and working-capital optimization; (3) ability to refinance or de-leverage the balance sheet and restore equity resilience; (4) potential strategic partnerships or licensing deals that monetize the eBalance ecosystem. Industry trends in home-based wellness devices and chronic-disease management support a favorable revenue trajectory if CMXC can convert pilots into scalable revenue streams, but the near-term risk remains elevated due to liquidity and equity concerns. Key factors to monitor include quarterly cash burn, any capital-raising activity, debt maturities, regulatory/commercial milestones for the eBalance platform, and the rate of user adoption in professional vs. home-use channels.